Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is
a leading global gastrointestinal (GI) healthcare company on a mission to
advance the treatment of GI diseases and redefine the standard of care for
GI patients. We are pioneers in the development of LINZESS® (linaclotide),
the U.S. branded prescription market leader for adults with irritable
bowel syndrome with constipation (IBS-C) or chronic idiopathic
constipation (CIC). LINZESS is also approved for the treatment of
functional constipation in pediatric patients ages 6-17 years-old.
Ironwood is also advancing apraglutide, a next-generation, long-acting
synthetic GLP-2 analog being developed for rare gastrointestinal diseases,
including short bowel syndrome with intestinal failure (SBS-IF), as well
as several earlier stage assets. Building upon our history of GI
innovation, we keep patients at the heart of our R&D and commercialization
efforts to reduce the burden of GI diseases and address significant unmet
needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.